Percutaneous transluminal coronary angioplasty (PTCA) also called percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked or stenosed coronary arteries allowing unobstructed blood flow to the myocardium. The blockage occurs because of lipid-rich plaque within the arteries, diminishing blood flow to the myocardium. The accumulation of lipid-rich plaque in the arteries is known as atherosclerosis, and when atherosclerosis affects the coronary arteries, the disorder is known as coronary artery disease.
A PTCA catheter is a device that operates on the principle of hydraulic pressurization applied through an inflatable balloon attached to the distal end. A PTCA balloon catheter has a single or double lumen shaft. The catheter features a balloon of appropriate compliance for clinical application, constructed from a polymer.
The percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market is estimated to be valued at US$ 2.2 Billion in 2022 and is expected to exhibit a CAGR of 8 % over the forecast period (2022-2030)
Figure 1. Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Value (US$ Mn), By Region, 2022
Increasing cardiovascular disease epidemiology worldwide is expected to boost the percutaneous transluminal coronary angioplasty (PTCA) market growth over the forecast period.
For instance, according to the data published in the Centers for Disease Control and Prevention in 2020, in the year 2020, about 20.1 million adults age 20 and older had cardiovascular diseases (about 7.2%), and about 2 in 10 deaths from cardiovascular diseases happened in adults less than 65 years old in U.S.
|Base Year:||2021||Market Size in 2022:||US$ 2.2 Bn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||8%||2030 Value Projection:||US$ 4.1 Bn|
Cook Group, Medtronic Plc., Becton Dickinson and Company, Abbott, Koninklijke Philips N.V., ENDOCOR GmbH, Cardinal Health, NIPRO, Terumo Corporation, Boston Scientific Corporation, Surmodics, Inc., Teleflex Incorporated, BIOTRONIK SE & Co. KG, Biomerics, Shockwave Medical Inc., Microport Scientific Corporation, Nordson Corporation, and S3V Vascular Technologies Pvt. Ltd.
|Restraints & Challenges:||
Figure 2. Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Share (%), By Product Type, 2022
Increasing product launches and approvals are expected to drive the growth of the percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market over the forecast period.
For instance, in July 2021, MedAlliance, a medical technology company headquartered in Switzerland, had launched ORIGIN NC, two high-performance balloons for vessel preparation. ORIGIN SC is a semi-compliant (SC) PTCA with a very low crossing profile. Its sizes include 1.00 mm, 1.25 mm, 1.50 mm, and 1.75 mm balloon diameter to treat very small vessels and complex cases.
ORIGIN NC is a non-compliant (NC) PTCA balloon, combining high-pressure tolerance and controlled compliance with an optimal crossing profile for challenging cases.
Moreover, in August 2018, S3V Vascular Technologies Private Limited, a medical devices manufacturing company, launched Nextgen PTCA (Percutaneous Transluminal Coronary Angioplasty) Balloon Catheters.
Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 583,038,110 cases of coronavirus disease (COVID-19) were reported till August 9, 2022, across the globe.
Cardiac surgery patients have an increased risk of complications from COVID-19 and require vital finite resources such as intensive care beds, and same needed by the covid-19 patient, thus admission of cardiac patient was reduced during the peak of covid-19 spread. Moreover, only emergencies such as acute aortic dissections were treated.
Moreover, according to an article published by CTV new in September 2021, Hamilton General Hospital had to cancel all cardiac surgeries for an entire day as it scramble to free up resources to care for COVID-19 patients in its intensive care unit.
Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Restraint
Increasing product recalls are expected to hinder the growth of the percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market over the forecast period. For instance, in February 2020, Abbott, a medical device and healthcare company, had voluntarily recalled specific lots of two types of its coronary angioplasty catheters – NC Trek RX Coronary Dilatation Catheter and NC Traveler Coronary Dilatation Catheter, as the balloons from the impacted lots may not deflect as intended, and the U.S Food and Drug Administration has classified this as Class I recall.
Major players operating in the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market include Cook Group, Medtronic Plc., Becton, Dickinson and Company, Abbott, Koninklijke Philips N.V., ENDOCOR GmbH, Cardinal Health, NIPRO, Terumo Corporation, Boston Scientific Corporation, Surmodics, Inc., Teleflex Incorporated, BIOTRONIK SE & Co. KG, Biomerics, Shockwave Medical Inc., Microport Scientific Corporation, Nordson Corporation, and S3V Vascular Technologies Pvt. Ltd.
Percutaneous transluminal coronary angioplasty is commonly called PTCA, or just angioplasty. A catheter is inserted into an artery usually into the groin and sometimes in the arm or wrist. The catheter is advanced to the heart, and a series of x-ray pictures are taken to clearly visualize the heart arteries that are narrowed. Then, a balloon-tipped catheter is advanced to the heart, and into the narrow coronary artery. Inside the artery, the balloon is inflated and deflated several times, compressing the plaque against the artery wall and widening the artery for the blood flow to improve. X-rays pictures are repeated, and if the artery has been successfully re-opened, the catheters are removed.
The increasing coronary artery disease population, rising research and development activities, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market over the forecast period.
For instance, in May 2022, Medtronic, a medical device company, announced that it received approval from the U.S food and drug administration (FDA) for IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter, a drug coated balloon (DCB), indicated for the interventional treatment of peripheral artery disease (PAD) in the superficial and popliteal arteries.
Moreover, according to the data published in American Heart Association in July 2021, lower extremity peripheral artery disease (PAD) affects more than 230 million adults worldwide.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients